source
- Biogen’s ALS drug shows symptom improvement in some patients three years after approvalBiogen’s antisense therapy tofersen, marketed as Qalsody, received FDA approval three years ago as the first treatment to target a genetic form of ALS linked to the SOD1 gene. Since then, a number…
- Denali Therapeutics' Avlayah generates $3.6M in Q1, beating forecastsDenali Therapeutics reported that its newly launched Hunter syndrome therapy Avlayah earned $3.6 million in revenue during the first quarter after its April market entry. Analysts had projected ro…